Trusted Resources: Education
Scientific literature and patient education texts
Therapy for AL Amyloidosis 2022
source: Amyloidosis Support Groups
year: 2022
authors: Jeffrey Zonder
summary/abstract:Antibodies (Plasma Cells) Therapy for AL Amyloidosis 2022 lists different medications and therapies for treating AL amyloidosis, a blood disorder characterized by abnormal deposits of a protein called immunoglobulin light chain in various organs and tissues of the body. The table is divided into several categories: Alkylating Agents, Proteasome Inhibitors, Steroids, IMiDs, Fibril-Directed Agents, and Light Chain Stabilizers. Some of the therapies listed in the table have FDA approval. The FDA-approved medication for AL Amyloidosis is Dara-CyBorD, a combination of Daratumumab, Cyclophosphamide, Bortezomib, and Dexamethasone.
read more
Related Content
-
Q&A Session on AL Amyloidosis – ASG Webinarhttps://www.youtube.com/watch?v=kvNVKAgl...
-
ISA Virtual Workshop on Gaps in Diagnosis and Management of AL Amyloidosishttps://vimeo.com/645401404...
-
Chicago – Amyloidosis Support Groups Meeting – LIVE – Saturday, September 9, 2023This Meeting Is for AL Amyloidosis Only ...
-
University of California San Francisco Cardiac Amyloidosis ProgramThe University of California San Francis...
-
Cardiac Amyloidosis Diagnostic Workuphttps://www.youtube.com/watch?v=gaWfWCph...
-
Cardiac Amyloidosis – the Great Imitatorhttps://www.youtube.com/watch?v=7DQotydY...
-
Why There’s New Hope if You Have Cardiac AmyloidosisAmyloidosis is a disorder in which c...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.